Can clozapine or Abilify (aripiprazole) increase the risk of pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clozapine Increases Risk of Pulmonary Embolism; Aripiprazole Does Not

Yes, clozapine significantly increases the risk of pulmonary embolism (PE), while aripiprazole (Abilify) does not carry this risk and may actually be protective when combined with clozapine.

Clozapine and PE Risk

The FDA drug label explicitly warns that pulmonary embolism and deep-vein thrombosis have occurred in patients treated with clozapine 1. This is a recognized serious adverse effect requiring clinical vigilance. The most recent 2026 Lancet Psychiatry consensus guidelines specifically list pulmonary embolism among the less common but serious adverse events that can impact patients on clozapine 2.

Clinical Evidence and Magnitude of Risk

Recent pharmacovigilance data from VigiBase (2026) demonstrates clozapine has a statistically significant PE signal with an information component (IC) of 0.93, representing 1,314 PE cases versus 688 expected 3. Most concerning is the 41% fatality rate among clozapine-associated PE cases 3. UK pharmacovigilance data (1990-2022) confirms this high mortality, showing 48% of clozapine-related PE cases resulted in death 4.

Timing and Risk Factors

PE can occur at any point during clozapine treatment:

  • 39% of non-fatal and 22% of fatal PEs occur within the first year 4
  • Median time to onset is 2.9 years, but cases range from 2 days to 22.7 years 4
  • Risk appears independent of dose (mean 337 mg/day, range 25-1000 mg) 4

Key risk factors for fatal outcomes include:

  • Obesity (adjusted OR 2.61) 4
  • Sedentary lifestyle (adjusted OR 6.07) 4

Importantly, PE can occur even in patients with minimal or no traditional VTE risk factors 5, 6, making risk stratification challenging.

Aripiprazole and PE Risk

In stark contrast, aripiprazole shows no significant PE signal in the same VigiBase analysis that identified clozapine and olanzapine as high-risk 3. The 2021 guideline on antipsychotic polypharmacy found that clozapine combined with aripiprazole was associated with the lowest risk of all-cause hospitalization (22% reduced risk) and all-cause mortality (24% reduced risk) compared to clozapine monotherapy 7.

While one case report describes PE in a patient on amisulpride and aripiprazole combination, the authors attributed the event primarily to amisulpride-induced hyperprolactinemia rather than aripiprazole 8.

Clinical Management Algorithm

When PE occurs on clozapine:

  1. Immediate discontinuation is standard practice 1 - though rare cases of continuation under anticoagulation with multidisciplinary oversight have been reported 9, 10

  2. Present with high clinical suspicion if patient develops:

    • Acute dyspnea
    • Chest pain
    • Deep vein thrombosis signs
    • Any respiratory symptoms 1
  3. After clozapine discontinuation for PE:

    • Aripiprazole represents a safer alternative without PE risk
    • Consider olanzapine cautiously (IC=1.2, highest PE signal among antipsychotics, 28% fatality rate) 3
    • Combination strategies like xanomeline-trospium with olanzapine may be considered for treatment-resistant cases 10

Critical Pitfalls

  • Do not assume traditional VTE risk factors must be present - PE occurs in patients with minimal risk factors 5, 6
  • Do not attribute early respiratory symptoms to other causes (e.g., COVID-19) without ruling out PE 5
  • Do not underestimate mortality risk - approximately 40% of clozapine-associated PEs are fatal 4, 3
  • No validated guidelines exist for prophylactic anticoagulation in clozapine patients 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.